Merck Will Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast

Merck Will Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast at 5:30 PM (EDT) on July 21

WHITEHOUSE STATION, N.J., July 21, 2008 - Merck & Co., Inc. will hold its second-quarter 2008 sales and earnings conference call with institutional investors and analysts to begin at 5:30 p.m. EDT on Monday, July 21, instead of the previously scheduled 9 a.m. EDT.  The second-quarter sales and earnings news release and supplemental financial disclosures will be distributed after the close of market today.
 
Merck made the second-quarter earnings schedule change because Terje Pedersen, M.D., PhD, Chief, Preventive Medicine Clinic, Ullevål University Hospital, Oslo, Norway, and the primary investigator of Simvastatin plus Ezetimibe in Aortic Stenosis (SEAS) Study, will present an update on the study later today. 

For Merck's sales and earnings conference call, journalists are invited to listen only by calling (706) 758-9928 or (800) 399-7917.  A replay of the call will be available starting at 11 p.m. EDT today through 5 p.m. EDT on July 28.  At the conclusion of the call, journalists who wish to ask questions are invited to call Media Relations.  To listen to the replay, dial (706) 645-9291 or (800) 642-1687 and enter ID No. 52725425.

Investors, journalists and the general public may access a live audio webcast of the call on Merck's Web site at http://www.merck.com/newsroom/webcast.  Software needed to listen to the webcast is available on the corporate Web site and should be downloaded prior to the beginning of the webcast.  A replay of the webcast will be available from 11 p.m. EDT today through 5 p.m. EDT on July 28.  The second-quarter sales and earnings press release and supplemental financial disclosures also will be available in the Newsroom.

About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.  Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.  The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them.  Merck also publishes unbiased health information as a not-for-profit service.  For more information, visit www.merck.com.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.